These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27449297)

  • 1. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
    An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
    Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel CBL-Bflox/flox mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells.
    Goetz B; An W; Mohapatra B; Zutshi N; Iseka F; Storck MD; Meza J; Sheinin Y; Band V; Band H
    Oncotarget; 2016 Aug; 7(32):51107-51123. PubMed ID: 27276677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
    Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
    Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.
    Naramura M; Nandwani N; Gu H; Band V; Band H
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16274-9. PubMed ID: 20805496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.
    William BM; An W; Feng D; Nadeau S; Mohapatra BC; Storck MA; Band V; Band H
    Hematology; 2016 May; 21(4):218-24. PubMed ID: 26177294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
    An W; Nadeau SA; Mohapatra BC; Feng D; Zutshi N; Storck MD; Arya P; Talmadge JE; Meza JL; Band V; Band H
    Oncotarget; 2015 Apr; 6(12):10498-509. PubMed ID: 25871390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.
    Pérez B; Mechinaud F; Galambrun C; Ben Romdhane N; Isidor B; Philip N; Derain-Court J; Cassinat B; Lachenaud J; Kaltenbach S; Salmon A; Désirée C; Pereira S; Menot ML; Royer N; Fenneteau O; Baruchel A; Chomienne C; Verloes A; Cavé H
    J Med Genet; 2010 Oct; 47(10):686-91. PubMed ID: 20543203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.
    Bunda S; Qin K; Kommaraju K; Heir P; Ohh M
    Oncogene; 2015 Feb; 34(6):789-97. PubMed ID: 24469048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
    Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
    Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
    Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.
    Liu YL; Yan Y; Webster C; Shao L; Lensing SY; Ni H; Feng W; Colorado N; Pathak R; Xiang Z; Hauer-Jensen M; Li S; Zhou D; Emanuel PD
    Blood; 2016 Apr; 127(15):1912-22. PubMed ID: 26764354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.
    Muraoka M; Okuma C; Kanamitsu K; Ishida H; Kanazawa Y; Washio K; Seki M; Kato M; Takita J; Sato Y; Ogawa S; Tsukahara H; Oda M; Shimada A
    J Hum Genet; 2016 Jun; 61(6):523-6. PubMed ID: 26911351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.
    Pathak A; Pemov A; McMaster ML; Dewan R; Ravichandran S; Pak E; Dutra A; Lee HJ; Vogt A; Zhang X; Yeager M; Anderson S; Kirby M; ; ; Caporaso N; Greene MH; Goldin LR; Stewart DR
    Hum Genet; 2015 Jul; 134(7):775-87. PubMed ID: 25939664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.
    Hecht A; Meyer JA; Behnert A; Wong E; Chehab F; Olshen A; Hechmer A; Aftandilian C; Bhat R; Choi SW; Chonat S; Farrar JE; Fluchel M; Frangoul H; Han JH; Kolb EA; Kuo DJ; MacMillan ML; Maese L; Maloney KW; Narendran A; Oshrine B; Schultz KR; Sulis ML; Van Mater D; Tasian SK; Hofmann WK; Loh ML; Stieglitz E
    Haematologica; 2022 Jan; 107(1):178-186. PubMed ID: 33375775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Graft Failure but Treatment Success: A Case of Reversion to Heterozygosity After Allogeneic Hematopoietic Cell Transplantation With Autologous Hematopoietic Recovery in a Child With CBL-related Juvenile Myelomonocytic Leukemia.
    Oshrine B
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e426-e428. PubMed ID: 32032248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
    Hyakuna N; Muramatsu H; Higa T; Chinen Y; Wang X; Kojima S
    Pediatr Blood Cancer; 2015 Mar; 62(3):542-4. PubMed ID: 25283271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
    Niemeyer CM; Kang MW; Shin DH; Furlan I; Erlacher M; Bunin NJ; Bunda S; Finklestein JZ; Gorr TA; Mehta P; Schmid I; Kropshofer G; Corbacioglu S; Lang PJ; Klein C; Schlegel PG; Heinzmann A; Schneider M; Starý J; van den Heuvel-Eibrink MM; Hasle H; Locatelli F; Sakai D; Archambeault S; Chen L; Russell RC; Sybingco SS; Ohh M; Braun BS; Flotho C; Loh ML
    Nat Genet; 2010 Sep; 42(9):794-800. PubMed ID: 20694012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.